Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 chemical drug, KH629, which is intended for the treatment of non-alcoholic steatohepatitis (NASH).
KH629’s Profile and Previous Studies
KH629 is an oral selective thyroid hormone β receptor agonist that has demonstrated promising safety and therapeutic effects on NASH in previous studies. The drug’s mechanism of action targets the thyroid hormone β receptor, which plays a crucial role in regulating metabolism and energy expenditure, offering a potential new approach to managing NASH.
Clinical Trial Significance
The approval to proceed with clinical trials in the US is a significant milestone for Chengdu Kanghong Pharmaceutical. It indicates the potential of KH629 to become a leading treatment option for NASH, a condition that affects a significant number of individuals worldwide and lacks approved pharmacological therapies. The clinical trial will provide valuable data on the drug’s efficacy and safety profile, bringing it one step closer to becoming a viable treatment for patients suffering from this liver disease.-Fineline Info & Tech
